Roffman Miller Associates’s GSK GSK Stock Holding History

Roffman Miller Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,346	Closed	-$273K	–	101
2020 Q2	$273K	Buy	+5,346	New	+$274K	0.03%	124
2019 Q3	–	Sell	-4,935	Closed	-$247K	–	94
2019 Q2	$247K	Buy	4,935 +1,041	+27%	+$52.2K	0.03%	82
2019 Q1	$204K	Buy	+3,894	New	+$195K	0.02%	80
2018 Q4	–	Sell	-4,542	Closed	-$228K	–	77
2018 Q3	$228K	Hold	4,542	–	–	0.03%	81
2018 Q2	$229K	Buy	4,542 +2	+0%	+$101	0.03%	62
2018 Q1	$222K	Sell	4,540 -606	-12%	-$28.2K	0.03%	62
2017 Q4	$228K	Sell	5,146 -90	-2%	-$4.16K	0.03%	62
2017 Q3	$266K	Sell	5,236 -499	-9%	-$25.3K	0.04%	62
2017 Q2	$309K	Sell	5,735 -1,431	-20%	-$76.3K	0.04%	62
2017 Q1	$378K	Buy	7,166 +1,736	+32%	+$88.1K	0.05%	60
2016 Q4	$261K	Sell	5,430 -1,772	-25%	-$87.5K	0.04%	61
2016 Q3	$388K	Sell	7,202 -8	-0.1%	-$439	0.06%	59
2016 Q2	$391K	Buy	7,210 +60	+0.8%	+$3.16K	0.06%	61
2016 Q1	$362K	Buy	7,150 +1,531	+27%	+$76.3K	0.06%	61
2015 Q4	$283K	Sell	5,619 -269	-5%	-$13.7K	0.05%	61
2015 Q3	$283K	Buy	5,888 +672	+13%	+$35K	0.06%	62
2015 Q2	$272K	Buy	5,216 +2	+0%	+$113	0.05%	62
2015 Q1	$301K	Hold	5,214	–	–	0.06%	61
2014 Q4	$279K	Buy	5,214 +214	+4%	+$12K	0.05%	62
2014 Q3	$287K	Buy	5,000 +1	+0%	+$61	0.06%	63
2014 Q2	$334K	Sell	4,999 -2,683	-35%	-$182K	0.07%	62
2014 Q1	$513K	Sell	7,682 -6,047	-44%	-$409K	0.11%	61
2013 Q4	$916K	Sell	13,729 -77,813	-85%	-$5.05M	0.21%	60
2013 Q3	$5.74M	Buy	91,542 +2,052	+2%	+$132K	1.45%	34
2013 Q2	$5.59M	Buy	+89,490	New	+$5.68M	1.49%	32

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Roffman Miller Associates's GSK Position: Q3 2020 in Review

Roffman Miller Associates sold out of GSK (GSK) in Q3 2020, closing a stake of 5,346 shares — an estimated $273K sold.

Roffman Miller Associates first reported a position in GSK in Q2 2013 and held it in 25 quarters. The position peaked at $5.74M in Q3 2013. 826 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

Roffman Miller Associates reported no remaining GSK position as of Q3 2020 after selling out during the quarter.
Roffman Miller Associates sold 5,346 GSK shares in Q3 2020, an estimated $273K.
Roffman Miller Associates first reported a position in GSK in Q2 2013 and held it in 25 quarters.
Roffman Miller Associates's GSK position peaked at $5.74M in Q3 2013.
826 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on Roffman Miller Associates's 13F filing for Q3 2020, filed 6 Nov 2020.